Key result
Prasugrel reduces 12-month death, MI, or stroke ~31% versus ticagrelor in ACS patients.
Why the study?
The efficacy and safety of ticagrelor versus prasugrel in patients with ACS according to time of hospital presentation remain unknown.
Does ticagrelor compared to prasugrel reduce the composite of death, myocardial infarction, or stroke in patients with ACS presenting during off-hours versus on-hours?
RCT (n=4,018)
Randomized to ticagrelor or prasugrel
Yes
Does ticagrelor compared to prasugrel reduce the composite of death, myocardial infarction, or stroke in patients with ACS presenting during off-hours versus on-hours?
Time of presentation does not significantly alter the relative efficacy and safety of ticagrelor versus prasugrel in patients with ACS undergoing an invasive strategy.
Answers are grounded in this paper and cite their sources.
Presentation time does not modify prasugrel's apparent benefit over ticagrelor in ACS; leaves open randomized confirmation of time-independent superiority.
Objectives To assess the efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndrome (ACS) presenting during off- and on-hours. Background The efficacy and safety of ticagrelor versus prasugrel in patients with ACS according to time of hospital presentation remain unknown. Methods This post hoc analysis of the ISAR-REACT 5 trial included 1565 patients with ACS presenting off-hours and 2453 patients presenting on-hours, randomized to ticagrelor or prasugrel. The primary endpoint was a composite of death, myocardial infarction, or stroke; the safety endpoint was Bleeding Academic Research Consortium (BARC) type 3–5 bleeding, both at 12 months. Results The primary endpoint occurred in 80 patients (10.4%) in the ticagrelor group and 57 patients (7.3%) in the prasugrel group in patients presenting off-hours (hazard ratio [HR] = 1.45; 95% confidence interval [CI] 1.03–2.03; P = 0.033), and 104 patients (8.5%) in the ticagrelor group and 80 patients (6.7%) in the prasugrel group in patients presenting on-hours (HR = 1.29 [0.97–1.73]; P = 0.085), without significant treatment arm-by-presentation time interaction (Pint = 0.62). BARC type 3 to 5 bleeding occurred in 35 patients (5.1%) in the ticagrelor group and 37 patients (5.3%) in the prasugrel group (P = 0.84) in patients presenting off-hours, and 60 patients (5.9%) in the ticagrelor group and 43 patients (4.6%) in the prasugrel group in patients presenting on-hours (P = 0.17). Conclusions In patients with ACS planned to undergo an invasive treatment strategy, time of presentation (off-hours vs. on-hours) does not interact significantly with the relative efficacy and safety of ticagrelor vs. prasugrel. Clinical trial registration. NCT01944800.
No takes yet. Share an insight, caveat, or question.
Behnes et al. (2022) conducted an RCT in Acute coronary syndrome (ACS) (n=4,018). Ticagrelor vs. Prasugrel (60 mg loading dose, 10 mg once daily maintenance) was evaluated on Composite of death, myocardial infarction, or stroke at 12 months (off-hours presentation subgroup) (HR 1.45, 95% CI 1.03-2.03, p=0.033). Prasugrel consistently reduced the 12-month risk of death, MI, or stroke compared with ticagrelor in ACS patients, with no significant interaction by off-hour versus on-hour presentation.
Synapse has enriched 10 related papers. Consider them for comparative context: